Sunitinib is used as a targeted therapy and a receptor protein-tyrosine kinase inhibitor for advanced renal cell cancer and gastrointensinal stromal tumor (GIST). Sunitinib is marketed under the name Sutent. The drug may also be used in combination with other chemotherapy drugs or for the treatment of other cancers.
Submit sites about the drug Sunitinib also referred to as Sutent.